Biofarm S.A. (H3D)
XFRA 
NASDAQ (CM) Primary XFRA Summary
H3D Chart
This stock rockets 260% after $900 million mega crypto deal
Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the company announced a $888 million business combination to pivot into the cryptocurrency sector.
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq:SONN), a clinical-stage company developing targeted immunotherapeutic drugs. As part of the "What This Means" segment, Pankaj Mohan, PhD, Founder and Chief Executive Officer, Richard Kenney, M.D.
Biofarm S.A. (H3D) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biofarm S.A. ever had a stock split?
Biofarm S.A. Profile
| Biotechnology Industry | Healthcare Sector | Raghu Rao CEO | XFRA Exchange | US83548R4020 ISIN |
| US Country | 13 Employees | - Last Dividend | 30 Sep 2024 Last Split | 31 Oct 2006 IPO Date |
Overview
Sonnet BioTherapeutics Holdings, Inc. is a pioneering biotechnology entity focused on the advancement of biologic medicines that exhibit single or bifunctional actions. Central to its innovative approach is the fully human albumin binding technology, a strategy that employs human single-chain antibodies fragment. This fragment leverages the natural properties of human serum albumin for targeted delivery to specific tissues. Situated in Princeton, New Jersey, Sonnet BioTherapeutics demonstrates a strong commitment to addressing complex medical conditions through advanced scientific methods and strategic partnerships, such as its licensing agreement with New Life Therapeutics Pte, LTD. for the development and commercialization of pharmaceutical preparations containing recombinant human interleukin-6.
Products and Services
- SON-1010
SON-1010 represents the forefront of Sonnet BioTherapeutics' pipeline, being a fully human single-chain variant of interleukin 12. This innovative biologic is currently undergoing a Phase 1b/2a clinical trial aimed at treating various solid tumor indications. The targeted cancers include ovarian cancer, non-small cell lung cancer, and head and neck cancer, showcasing the potential breadth of SON-1010's therapeutic applications and its promise in oncology.
- SON-080
A fully human version of interleukin 6, SON-080, is another key development within Sonnet BioTherapeutics' portfolio. It has entered the Phase 1b/I2a clinical trial phase, focusing on the treatment of conditions such as chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. This product highlights the company's dedication to addressing the adverse side effects of cancer treatments, thus improving patients' quality of life.
- SON-1210
SON-1210 is designed as a bispecific compound targeting solid tumor indications, which includes an ambitious approach toward treating colorectal cancer among others. By combining two mechanisms of action in one entity, SON-1210 exemplifies Sonnet BioTherapeutics' innovative approach to drug development, aiming to provide more effective solutions for cancer treatment.
